Hôpital Cochin

Paris 75679

12 studies enrolling now · 45 studies all time

What they study most

Advanced Cancer, Advanced Solid Tumors, Biliary Tract Cancer, Breast Cancer, Breast Neoplasms, Bronchiectasis, Cervical Cancer, Coagulopathy, Community-acquired Pneumonia, Coronary Artery Disease, Cystic Fibrosis, Cystic Fibrosis - Complete, ENSAT Stage I Adrenal Cortex Carcinoma

Studies at this site

• A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases — Recruiting now
• A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis — Recruiting now
• DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy — Recruiting now
• The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis — Recruiting now
• A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) — Recruiting now
• Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP) — Recruiting now
• DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers — Recruiting now
• Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence — Recruiting now
• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — Recruiting now
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — Recruiting now
• Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC — Recruiting now
• A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia — Recruiting now
• Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen — Recruiting now
• Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) — Running, not enrolling
• Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) — Running, not enrolling
• A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis — Running, not enrolling
• GEN1047 for Solid Tumors - First in Human (FIH) Trial — Stopped early
• A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™) — Completed
• A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain — Completed
• Vamikibart in Participants With Uveitic Macular Edema — Completed
• A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms — Completed
• Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma — Completed
• Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients — Running, not enrolling
• Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome — Running, not enrolling
• A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI — Running, not enrolling
• A Study of AGEN2034 in Advanced Tumors and Cervical Cancer — Completed
• Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients) — Running, not enrolling
• Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients — Completed
• Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment — Stopped early
• A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) — Completed
• A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage — Completed
• Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer — Stopped early
• Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors — Completed
• Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) — Stopped early
• Extension Study of Ataluren (PTC124) in Cystic Fibrosis — Completed
• Study of Ataluren (PTC124™) in Cystic Fibrosis — Completed
• Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis — Completed
• Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy — Completed
• EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients — Completed
• A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus — Completed
• Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis — Completed
• The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s) — Completed
• Gilead Sustained Virologic Response (SVR) Registry — Completed
• A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C — Completed
• Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis — Paused